Concept Life Sciences appoints Philip Payne as Chief Commercial Officer
News Oct 24, 2017
Concept Life Sciences announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth. Philip completes Concept’s leadership team, following the appointment in August of John Handley as COO.
Philip will work with Concept’s executive team and board to drive the group’s commercial strategy, leading the business development function and helping to guide the next stage of the Company’s growth. He will be responsible for managing the sales team, including identification of new service areas, geographies and markets, supporting the broadening of Concept’s reach into Europe and the US.
Philip has 27 years’ experience in managing the integration of business development in an international environment, and has gained cross-sector expertise through roles in pharma and biotech discovery as well as analytical and development services. He joins Concept from Aptuit, where he held various roles, including Vice President of Sales, and was responsible for the global business development team and strategic accounts. Prior to joining Aptuit he was Business Development Director Europe and Asia for Sterile Technologies at Catalent Pharma Solutions, and Pharmaceutical Business Development Director with Reading Scientific Services Ltd.
Michael Fort, Executive Chairman, Concept Life Sciences, said: “Philip’s experience in managing multidisciplinary, international teams across a range of industries will be a great asset as Concept’s rapid rate of expansion continues. Following on from John’s appointment as COO, Concept now has an extremely strong leadership team. We are delighted to welcome Philip to the group.”
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “I am excited to join Concept at this pivotal stage in the growth of the Company, and look forward to working with the team to meet the group’s commercial and strategic objectives.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE